Do analysts rate ANIK or ALPS?

Anika Therapeutics currently has a consensus price target of $22.00, suggesting a potential upside of 11.51%. Given Anika Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Anika Therapeutics is more favorable than ALPS Group Inc Ordinary Share. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anika Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 ALPS Group Inc Ordinary Share 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer GLSI or ALPS?

Greenwich LifeSciences currently has a consensus price target of $69.00, indicating a potential upside of 308.04%. Given Greenwich LifeSciences' stronger consensus rating and higher probable upside, equities analysts plainly believe Greenwich LifeSciences is more favorable than ALPS Group Inc Ordinary Share. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Greenwich LifeSciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 ALPS Group Inc Ordinary Share 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is GLSI or ALPS more profitable?

ALPS Group Inc Ordinary Share's return on equity of 0.00% beat Greenwich LifeSciences' return on equity. Company Net Margins Return on Equity Return on Assets Greenwich LifeSciences N/A -793.81% -295.32% ALPS Group Inc Ordinary Share N/A N/A N/A

Do analysts recommend IFRX or ALPS?

InflaRx presently has a consensus target price of $7.43, suggesting a potential upside of 342.18%. Given InflaRx's stronger consensus rating and higher probable upside, equities research analysts clearly believe InflaRx is more favorable than ALPS Group Inc Ordinary Share. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InflaRx 1 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.67 ALPS Group Inc Ordinary Share 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is IFRX or ALPS more profitable?

ALPS Group Inc Ordinary Share's return on equity of 0.00% beat InflaRx's return on equity. Company Net Margins Return on Equity Return on Assets InflaRx N/A -53.56% -43.02% ALPS Group Inc Ordinary Share N/A N/A N/A

Do analysts recommend ALPS or BCYC?

Bicycle Therapeutics has a consensus price target of $13.86, indicating a potential upside of 245.56%. Given Bicycle Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Bicycle Therapeutics is more favorable than ALPS Group Inc Ordinary Share. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ALPS Group Inc Ordinary Share 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Bicycle Therapeutics 1 Sell rating(s) 3 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.44

Do analysts recommend ALPS or GALT?

Galectin Therapeutics has a consensus price target of $11.00, suggesting a potential upside of 194.91%. Given Galectin Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Galectin Therapeutics is more favorable than ALPS Group Inc Ordinary Share. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ALPS Group Inc Ordinary Share 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Galectin Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is ALPS or GALT more profitable?

Company Net Margins Return on Equity Return on Assets ALPS Group Inc Ordinary Share N/A N/A N/A Galectin Therapeutics N/A N/A -176.83%

ALPS Group Inc Ordinary Share (ALPS) Competitors

$0.39 -0.01 (-3.58%)

Closing price 04:00 PM Eastern

Extended Trading

$0.41 +0.02 (+5.52%)

As of 07:18 PM Eastern

Compare

ALPS vs. ANIK, GLSI, IFRX, BCYC, and GALT

Should you buy ALPS Group Inc Ordinary Share stock or one of its competitors? ALPS Group Inc Ordinary Share's main competitors and comparable companies include Anika Therapeutics (ANIK), Greenwich LifeSciences (GLSI), InflaRx (IFRX), Bicycle Therapeutics (BCYC), and Galectin Therapeutics (GALT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does ALPS Group Inc Ordinary Share compare to Anika Therapeutics?

Anika Therapeutics (NASDAQ:ANIK) and ALPS Group Inc Ordinary Share (NASDAQ:ALPS) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, media sentiment, valuation, dividends and profitability.

ALPS Group Inc Ordinary Share has lower revenue, but higher earnings than Anika Therapeutics. Anika Therapeutics is trading at a lower price-to-earnings ratio than ALPS Group Inc Ordinary Share, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anika Therapeutics	$112.82M	2.34	-$10.88M	-$0.27	N/A
ALPS Group Inc Ordinary Share	$4.86M	13.70	-$2.01M	$0.26	1.54

In the previous week, Anika Therapeutics had 2 more articles in the media than ALPS Group Inc Ordinary Share. MarketBeat recorded 2 mentions for Anika Therapeutics and 0 mentions for ALPS Group Inc Ordinary Share. ALPS Group Inc Ordinary Share's average media sentiment score of 0.00 beat Anika Therapeutics' score of -0.70 indicating that ALPS Group Inc Ordinary Share is being referred to more favorably in the news media.

Company	Overall Sentiment
Anika Therapeutics	Negative
ALPS Group Inc Ordinary Share	Neutral

Anika Therapeutics currently has a consensus price target of $22.00, suggesting a potential upside of 11.51%. Given Anika Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Anika Therapeutics is more favorable than ALPS Group Inc Ordinary Share.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anika Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
ALPS Group Inc Ordinary Share	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Anika Therapeutics has a beta of 0.21, suggesting that its stock price is 79% less volatile than the broader market. Comparatively, ALPS Group Inc Ordinary Share has a beta of -0.11, suggesting that its stock price is 111% less volatile than the broader market.

ALPS Group Inc Ordinary Share has a net margin of 0.00% compared to Anika Therapeutics' net margin of -3.14%. Anika Therapeutics' return on equity of 0.20% beat ALPS Group Inc Ordinary Share's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anika Therapeutics	-3.14%	0.20%	0.15%
ALPS Group Inc Ordinary Share	N/A	N/A	N/A

91.5% of Anika Therapeutics shares are held by institutional investors. Comparatively, 27.9% of ALPS Group Inc Ordinary Share shares are held by institutional investors. 12.1% of Anika Therapeutics shares are held by company insiders. Comparatively, 0.8% of ALPS Group Inc Ordinary Share shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Anika Therapeutics beats ALPS Group Inc Ordinary Share on 10 of the 16 factors compared between the two stocks.

How does ALPS Group Inc Ordinary Share compare to Greenwich LifeSciences?

Greenwich LifeSciences (NASDAQ:GLSI) and ALPS Group Inc Ordinary Share (NASDAQ:ALPS) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, media sentiment, dividends, profitability, institutional ownership and valuation.

ALPS Group Inc Ordinary Share's return on equity of 0.00% beat Greenwich LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Greenwich LifeSciences	N/A	-793.81%	-295.32%
ALPS Group Inc Ordinary Share	N/A	N/A	N/A

In the previous week, Greenwich LifeSciences had 1 more articles in the media than ALPS Group Inc Ordinary Share. MarketBeat recorded 1 mentions for Greenwich LifeSciences and 0 mentions for ALPS Group Inc Ordinary Share. Greenwich LifeSciences' average media sentiment score of 0.00 equaled ALPS Group Inc Ordinary Share'saverage media sentiment score.

Company	Overall Sentiment
Greenwich LifeSciences	Neutral
ALPS Group Inc Ordinary Share	Neutral

Greenwich LifeSciences currently has a consensus price target of $69.00, indicating a potential upside of 308.04%. Given Greenwich LifeSciences' stronger consensus rating and higher probable upside, equities analysts plainly believe Greenwich LifeSciences is more favorable than ALPS Group Inc Ordinary Share.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Greenwich LifeSciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
ALPS Group Inc Ordinary Share	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Greenwich LifeSciences has a beta of 1.46, meaning that its share price is 46% more volatile than the broader market. Comparatively, ALPS Group Inc Ordinary Share has a beta of -0.11, meaning that its share price is 111% less volatile than the broader market.

ALPS Group Inc Ordinary Share has higher revenue and earnings than Greenwich LifeSciences. Greenwich LifeSciences is trading at a lower price-to-earnings ratio than ALPS Group Inc Ordinary Share, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Greenwich LifeSciences	N/A	N/A	-$19.36M	-$1.54	N/A
ALPS Group Inc Ordinary Share	$4.86M	13.70	-$2.01M	$0.26	1.54

4.2% of Greenwich LifeSciences shares are held by institutional investors. Comparatively, 27.9% of ALPS Group Inc Ordinary Share shares are held by institutional investors. 51.5% of Greenwich LifeSciences shares are held by company insiders. Comparatively, 0.8% of ALPS Group Inc Ordinary Share shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

ALPS Group Inc Ordinary Share beats Greenwich LifeSciences on 7 of the 13 factors compared between the two stocks.

How does ALPS Group Inc Ordinary Share compare to InflaRx?

InflaRx (NASDAQ:IFRX) and ALPS Group Inc Ordinary Share (NASDAQ:ALPS) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their media sentiment, earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.

ALPS Group Inc Ordinary Share has higher revenue and earnings than InflaRx. InflaRx is trading at a lower price-to-earnings ratio than ALPS Group Inc Ordinary Share, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InflaRx	$30K	8,252.72	-$51.63M	-$0.58	N/A
ALPS Group Inc Ordinary Share	$4.86M	13.70	-$2.01M	$0.26	1.54

InflaRx has a beta of 2.59, suggesting that its share price is 159% more volatile than the broader market. Comparatively, ALPS Group Inc Ordinary Share has a beta of -0.11, suggesting that its share price is 111% less volatile than the broader market.

InflaRx presently has a consensus target price of $7.43, suggesting a potential upside of 342.18%. Given InflaRx's stronger consensus rating and higher probable upside, equities research analysts clearly believe InflaRx is more favorable than ALPS Group Inc Ordinary Share.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InflaRx	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.67
ALPS Group Inc Ordinary Share	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

ALPS Group Inc Ordinary Share's return on equity of 0.00% beat InflaRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InflaRx	N/A	-53.56%	-43.02%
ALPS Group Inc Ordinary Share	N/A	N/A	N/A

In the previous week, InflaRx had 6 more articles in the media than ALPS Group Inc Ordinary Share. MarketBeat recorded 6 mentions for InflaRx and 0 mentions for ALPS Group Inc Ordinary Share. InflaRx's average media sentiment score of 0.29 beat ALPS Group Inc Ordinary Share's score of 0.00 indicating that InflaRx is being referred to more favorably in the media.

Company	Overall Sentiment
InflaRx	Neutral
ALPS Group Inc Ordinary Share	Neutral

42.4% of InflaRx shares are owned by institutional investors. Comparatively, 27.9% of ALPS Group Inc Ordinary Share shares are owned by institutional investors. 16.3% of InflaRx shares are owned by insiders. Comparatively, 0.8% of ALPS Group Inc Ordinary Share shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

InflaRx beats ALPS Group Inc Ordinary Share on 10 of the 16 factors compared between the two stocks.

How does ALPS Group Inc Ordinary Share compare to Bicycle Therapeutics?

ALPS Group Inc Ordinary Share (NASDAQ:ALPS) and Bicycle Therapeutics (NASDAQ:BCYC) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, analyst recommendations, dividends, institutional ownership and media sentiment.

In the previous week, Bicycle Therapeutics had 2 more articles in the media than ALPS Group Inc Ordinary Share. MarketBeat recorded 2 mentions for Bicycle Therapeutics and 0 mentions for ALPS Group Inc Ordinary Share. ALPS Group Inc Ordinary Share's average media sentiment score of 0.00 equaled Bicycle Therapeutics'average media sentiment score.

Company	Overall Sentiment
ALPS Group Inc Ordinary Share	Neutral
Bicycle Therapeutics	Neutral

ALPS Group Inc Ordinary Share has a beta of -0.11, meaning that its stock price is 111% less volatile than the broader market. Comparatively, Bicycle Therapeutics has a beta of 1.68, meaning that its stock price is 68% more volatile than the broader market.

Bicycle Therapeutics has a consensus price target of $13.86, indicating a potential upside of 245.56%. Given Bicycle Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Bicycle Therapeutics is more favorable than ALPS Group Inc Ordinary Share.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALPS Group Inc Ordinary Share	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Bicycle Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44

ALPS Group Inc Ordinary Share has a net margin of 0.00% compared to Bicycle Therapeutics' net margin of -311.11%. ALPS Group Inc Ordinary Share's return on equity of 0.00% beat Bicycle Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ALPS Group Inc Ordinary Share	N/A	N/A	N/A
Bicycle Therapeutics	-311.11%	-33.22%	-27.79%

ALPS Group Inc Ordinary Share has higher earnings, but lower revenue than Bicycle Therapeutics. Bicycle Therapeutics is trading at a lower price-to-earnings ratio than ALPS Group Inc Ordinary Share, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ALPS Group Inc Ordinary Share	$4.86M	13.70	-$2.01M	$0.26	1.54
Bicycle Therapeutics	$61.21M	4.59	-$218.96M	-$2.73	N/A

27.9% of ALPS Group Inc Ordinary Share shares are owned by institutional investors. Comparatively, 86.2% of Bicycle Therapeutics shares are owned by institutional investors. 0.8% of ALPS Group Inc Ordinary Share shares are owned by insiders. Comparatively, 22.0% of Bicycle Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Bicycle Therapeutics beats ALPS Group Inc Ordinary Share on 8 of the 15 factors compared between the two stocks.

How does ALPS Group Inc Ordinary Share compare to Galectin Therapeutics?

ALPS Group Inc Ordinary Share (NASDAQ:ALPS) and Galectin Therapeutics (NASDAQ:GALT) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, profitability, risk, institutional ownership, media sentiment, analyst recommendations and dividends.

27.9% of ALPS Group Inc Ordinary Share shares are owned by institutional investors. Comparatively, 11.7% of Galectin Therapeutics shares are owned by institutional investors. 0.8% of ALPS Group Inc Ordinary Share shares are owned by company insiders. Comparatively, 52.6% of Galectin Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Galectin Therapeutics has a consensus price target of $11.00, suggesting a potential upside of 194.91%. Given Galectin Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Galectin Therapeutics is more favorable than ALPS Group Inc Ordinary Share.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALPS Group Inc Ordinary Share	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Galectin Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

ALPS Group Inc Ordinary Share has a beta of -0.11, suggesting that its stock price is 111% less volatile than the broader market. Comparatively, Galectin Therapeutics has a beta of 0.38, suggesting that its stock price is 62% less volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
ALPS Group Inc Ordinary Share	N/A	N/A	N/A
Galectin Therapeutics	N/A	N/A	-176.83%

In the previous week, Galectin Therapeutics had 1 more articles in the media than ALPS Group Inc Ordinary Share. MarketBeat recorded 1 mentions for Galectin Therapeutics and 0 mentions for ALPS Group Inc Ordinary Share. Galectin Therapeutics' average media sentiment score of 0.67 beat ALPS Group Inc Ordinary Share's score of 0.00 indicating that Galectin Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
ALPS Group Inc Ordinary Share	Neutral
Galectin Therapeutics	Positive

ALPS Group Inc Ordinary Share has higher revenue and earnings than Galectin Therapeutics. Galectin Therapeutics is trading at a lower price-to-earnings ratio than ALPS Group Inc Ordinary Share, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ALPS Group Inc Ordinary Share	$4.86M	13.70	-$2.01M	$0.26	1.54
Galectin Therapeutics	N/A	N/A	-$30.84M	-$0.43	N/A

Summary

Galectin Therapeutics beats ALPS Group Inc Ordinary Share on 7 of the 13 factors compared between the two stocks.

Get ALPS Group Inc Ordinary Share News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALPS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALPS vs. The Competition

Export

Metric	ALPS Group Inc Ordinary Share	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$66.56M	$3.88B	$7.19B	$13.39B
Dividend Yield	N/A	3.65%	2.53%	18.16%
P/E Ratio	1.48	13.22	273.36	26.35
Price / Sales	13.21	1,232.19	591.83	96.77
Price / Cash	N/A	126.56	79.41	53.24
Price / Book	-0.12	16.64	11.04	6.33
Net Income	-$2.01M	-$23.16M	$3.49B	$381.26M
7 Day Performance	-3.55%	-4.05%	-2.30%	-0.61%
1 Month Performance	1.50%	-12.06%	-7.05%	-4.84%
1 Year Performance	N/A	14.68%	5.64%	1.12%

ALPS Group Inc Ordinary Share Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALPS ALPS Group Inc Ordinary Share	0.5682 of 5 stars	$0.39 -3.6%	N/A	N/A	$66.56M	$4.86M	1.48	93	Gap Down
ANIK Anika Therapeutics	2.9863 of 5 stars	$19.36 -1.5%	$22.00 +13.6%	+117.5%	$259.04M	$112.82M	N/A	235
GLSI Greenwich LifeSciences	2.1867 of 5 stars	$17.35 -3.9%	$69.00 +297.7%	+55.0%	$254.70M	N/A	N/A	13	Positive News
IFRX InflaRx	2.1526 of 5 stars	$1.71 -5.0%	$7.43 +334.4%	+6.3%	$252.00M	$30K	N/A	65
BCYC Bicycle Therapeutics	1.9698 of 5 stars	$3.56 -3.3%	$13.86 +289.2%	-52.1%	$249.16M	$72.86M	N/A	288	Trending News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALPS) was last updated on 10/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ALPS Group Inc Ordinary Share (ALPS) Competitors

ALPS vs. ANIK, GLSI, IFRX, BCYC, and GALT

How does ALPS Group Inc Ordinary Share compare to Anika Therapeutics?

Summary

How does ALPS Group Inc Ordinary Share compare to Greenwich LifeSciences?

Summary

How does ALPS Group Inc Ordinary Share compare to InflaRx?

Summary

How does ALPS Group Inc Ordinary Share compare to Bicycle Therapeutics?

Summary

How does ALPS Group Inc Ordinary Share compare to Galectin Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALPS vs. The Competition

ALPS Group Inc Ordinary Share Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ALPS Group Inc Ordinary Share (ALPS) Competitors

ALPS vs. ANIK, GLSI, IFRX, BCYC, and GALT

How does ALPS Group Inc Ordinary Share compare to Anika Therapeutics?

Which has stronger earnings and valuation, ANIK or ALPS?

Does the media refer more to ANIK or ALPS?

Do analysts rate ANIK or ALPS?

Which has more volatility and risk, ANIK or ALPS?

Is ANIK or ALPS more profitable?

Do insiders & institutionals believe in ANIK or ALPS?

Summary

How does ALPS Group Inc Ordinary Share compare to Greenwich LifeSciences?

Is GLSI or ALPS more profitable?

Does the media favor GLSI or ALPS?

Do analysts prefer GLSI or ALPS?

Which has more risk & volatility, GLSI or ALPS?

Which has better valuation and earnings, GLSI or ALPS?

Do institutionals & insiders have more ownership in GLSI or ALPS?

Summary

How does ALPS Group Inc Ordinary Share compare to InflaRx?

Which has preferable earnings and valuation, IFRX or ALPS?

Which has more volatility & risk, IFRX or ALPS?

Do analysts recommend IFRX or ALPS?

Is IFRX or ALPS more profitable?

Does the media favor IFRX or ALPS?

Do institutionals & insiders hold more shares of IFRX or ALPS?

Summary

How does ALPS Group Inc Ordinary Share compare to Bicycle Therapeutics?

Does the media prefer ALPS or BCYC?

Which has more volatility and risk, ALPS or BCYC?

Do analysts recommend ALPS or BCYC?

Is ALPS or BCYC more profitable?

Which has higher earnings and valuation, ALPS or BCYC?

Do institutionals and insiders have more ownership in ALPS or BCYC?

Summary

How does ALPS Group Inc Ordinary Share compare to Galectin Therapeutics?

Do insiders & institutionals hold more shares of ALPS or GALT?

Do analysts recommend ALPS or GALT?

Which has more volatility & risk, ALPS or GALT?

Is ALPS or GALT more profitable?

Does the media refer more to ALPS or GALT?

Which has higher valuation & earnings, ALPS or GALT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALPS vs. The Competition

ALPS Group Inc Ordinary Share Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools